A Phase 1 Study of BPI-28592 in Subjects With Advanced Solid Tumors

Betta Pharmaceuticals

Status and phase: Unknown; Phase 1

Conditions: Metastasis, Neoplasm

Treatments: Drug: BPI-28592

Study type: Interventional

Funder types: Industry

Identifiers

NCT05302843

BTP-661211

Details and patient eligibility

About

This is an open-labe Phase I study of BPI-28592 for the treatment of patients with solid tumors

Enrollment: 40 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Histologically- or cytologically-confirmed diagnosis of locally advanced or metastatic solid tumor
• At least 18 years of age
• Measurable or evaluable disease
• Adequate organ function as defined per protocol

Exclusion criteria

• Symptomatic or unstable brain metastases
• Pregnancy or lactation
• Other protocol specified criteria

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

40 participants in 1 patient group

dose exploration and dose expansion

Experimental group

Description:

Patients receive BPI-28592 PO. Cycles repeat every 28 days.

Treatment:

Drug: BPI-28592